BEDFORD, Mass.--(BUSINESS WIRE)--Sep. 16, 2014--
Ocular Therapeutix (Nasdaq: OCUL), a biopharmaceutical company focused
on the development and commercialization of innovative therapies for
diseases and conditions of the eye, today announced that Amar Sawhney,
Ph.D., President and Chief Executive Officer, will provide an overview
of the Company at the 21st Annual BioCentury Conference during a live
presentation at 3:30pm ET on September 26, 2014. Dr. Sawhney and other
members of the Company’s management team will also be available to
participate in one-on-one meetings with investors who are registered to
attend the conference. The event will be held at the Millennium Broadway
Hotel & Conference Center in New York. A live webcast will be accessible
through Ocular’s website at www.oculartherapeutix.com
in the Investors section under Calendar of Events. A replay of the
presentation will also be available.
About Ocular Therapeutix
Ocular Therapeutix, Inc. is a biopharmaceutical company focused on the
development and commercialization of innovative therapies for diseases
and conditions of the eye using its proprietary hydrogel platform
technology. Ocular Therapeutix’s lead product candidates are in Phase 3
clinical development for post-surgical ocular inflammation and pain, and
Phase 2 clinical development for glaucoma and allergic conjunctivitis.
The Company is also evaluating sustained-release injectable anti-VEGF
drug depots for back-of-the-eye diseases. Ocular Therapeutix’s first
product, ReSure® Sealant, is FDA-approved to seal corneal incisions
following cataract surgery.
Source: Ocular Therapeutix, Inc.
Investors:
Ocular Therapeutix, Inc.
Brad Smith
Chief
Financial Officer
bsmith@ocutx.com
or
Burns
McClellan on behalf of Ocular Therapeutix
Kimberly Minarovich,
212-213-0006
kminarovich@burnsmc.com
or
Media:
Scott
Corning
Vice President of Sales and Marketing
scorning@ocutx.com
